LEADER 04569nam 22007334a 450 001 9910968977103321 005 20251017110102.0 010 $a9786610447220 010 $a9780309164887 010 $a0309164885 010 $a9781280447228 010 $a1280447222 010 $a9780309655231 010 $a0309655234 035 $a(CKB)1000000000245196 035 $a(EBL)3378064 035 $a(SSID)ssj0000233534 035 $a(PQKBManifestationID)12085775 035 $a(PQKBTitleCode)TC0000233534 035 $a(PQKBWorkID)10220644 035 $a(PQKB)11187287 035 $a(Au-PeEL)EBL3378064 035 $a(CaPaEBR)ebr10120231 035 $a(CaONFJC)MIL44722 035 $a(OCoLC)923275191 035 $a(MiAaPQ)EBC3378064 035 $a(Perlego)4734277 035 $a(DNLM)1277476 035 $a(BIP)13173335 035 $a(EXLCZ)991000000000245196 100 $a20060207d2006 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aReaping the benefits of genomic and proteomic research $eintellectual property rights, innovation, and public health /$fCommittee on Intellectual Property Rights in Genomic and Protein Research and Innovation, Board on Science, Technology, and Economic Policy, Committee on Science, Technology, and Law Policy and Global Affairs, National Research Council of the National Academies ; Stephen A. Merrill and Anne-Marie Mazza, editors 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$dc2006 215 $a1 online resource (188 p.) 300 $aDescription based upon print version of record. 311 08$a9780309100670 311 08$a0309100674 320 $aIncludes bibliographical references (p. 150-154). 327 $a""Front Matter""; ""Preface and Acknowledgments""; ""Contents""; ""List of Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 Genomics, Proteomics, and the Changing Research Environment""; ""3 The U.S. Patent System, Biotechnology, and the Courts""; ""4 Trends in the Patenting and Licensing of Genomic and Protein Inventions and Their Impact on Biomedical Research""; ""5 Conclusions and Recommendations""; ""References""; ""Appendixes""; ""Appendix A Biographical Information of Committee and Staff""; ""Appendix B Search Algorithms Used to Identify Patents of Interest"" 330 $aThe patenting and licensing of human genetic material and proteins represents an extension of intellectual property (IP) rights to naturally occurring biological material and scientific information, much of it well upstream of drugs and other disease therapies. This report concludes that IP restrictions rarely impose significant burdens on biomedical research, but there are reasons to be apprehensive about their future impact on scientific advances in this area. The report recommends 13 actions that policy-makers, courts, universities, and health and patent officials should take to prevent the increasingly complex web of IP protections from getting in the way of potential breakthroughs in genomic and proteomic research. It endorses the National Institutes of Health guidelines for technology licensing, data sharing, and research material exchanges and says that oversight of compliance should be strengthened. It recommends enactment of a statutory exception from infringement liability for research on a patented invention and raising the bar somewhat to qualify for a patent on upstream research discoveries in biotechnology. With respect to genetic diagnostic tests to detect patient mutations associated with certain diseases, the report urges patent holders to allow others to perform the tests for purposes of verifying the results. 606 $aGenomics$zUnited States$vPatents 606 $aProteomics$zUnited States$vPatents 606 $aIntellectual property$zUnited States 615 0$aGenomics 615 0$aProteomics 615 0$aIntellectual property 676 $a572.8 701 $aMerrill$b Stephen A$01807734 701 $aMazza$b Anne-Marie$01805100 712 02$aNational Research Council (U.S.).$bCommittee on Intellectual Property Rights in Genomic and Protein Research and Innovation. 712 02$aNational Research Council (U.S.).$bCommittee on Science, Technology, and Law. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910968977103321 996 $aReaping the benefits of genomic and proteomic research$94360369 997 $aUNINA